3.70
0.00 (0.00%)
| Penutupan Terdahulu | 3.70 |
| Buka | 3.73 |
| Jumlah Dagangan | 13,795 |
| Purata Dagangan (3B) | 66,369 |
| Modal Pasaran | 31,294,478 |
| Harga / Buku (P/B) | 2.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Feb 2026 |
| EPS Cair (TTM) | -12.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 131.68% |
| Nisbah Semasa (MRQ) | 0.550 |
| Aliran Tunai Operasi (OCF TTM) | -17.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.55 M |
| Pulangan Atas Aset (ROA TTM) | -62.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -244.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cel-Sci Corporation | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.98% |
| % Dimiliki oleh Institusi | 3.80% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mai Capital Management | 31 Dec 2025 | 89,723 |
| Us Bancorp \De\ | 31 Dec 2025 | 18,413 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Dec 2025 | Pengumuman | CEL-SCI Reports Fiscal 2025 Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |